A Case of Stuttering During Treatment with Levomepromazine

Stuttering is a disturbance in the normal fluency and time patterning of speech, characterized by sound and syllable repetitions, sound prolongations and broken words. Acquired stuttering that begins in adulthood is rather unusual. It might be associated with different neurological disorders, like traumatic brain injuries, strokes, or extrapyramidal diseases. Rarely, it has been also reported as a side effect of different psychopharmacologic drugs, including selective serotonin reuptake inhibitors, tricyclic antidepressants, phenothiazines, olanzapine, clozapine¹ and risperidone.² To our best knowledge, there is only one article with descriptions of two patients who developed stuttering as a dose-dependent side effect of treatment with three different phenothiazine antipsychotics (chlorpromazine, trifluoperazine, and fluphenazine).³ However, a case of stuttering associated with the use of levomepromazine (also known as mepromazine or methotrimeprazine) has so far not been reported. Levomepromazine is a low-potency aliphatic phenothiazine antipsychotic characterized by strong sedative abilities⁴ and 5-HT2A:D2 affinity ratio 5:1.⁵ We present a case in which levomepromazine was implicated as a potential cause of stuttering.

Authors

Publication Details

Journal
Psychopharmacology Bulletin
Published
2025-08-12
DOI
https://doi.org/10.64719/pb.4332
Citations
5
Primary Topic
Stuttering Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Case of Stuttering During Treatment with Levomepromazine

Branko Krajinović, Branka Aukst‐Margetić, Branimir Margetić
5 citations
Psychopharmacology Bulletin
Stuttering Research and Treatment
article

A Case of Stuttering During Treatment with Levomepromazine

Branko Krajinović, Branka Aukst‐Margetić, Branimir Margetić
article en
5 citations

Abstract

Stuttering is a disturbance in the normal fluency and time patterning of speech, characterized by sound and syllable repetitions, sound prolongations and broken words. Acquired stuttering that begins in adulthood is rather unusual. It might be associated with different neurological disorders, like traumatic brain injuries, strokes, or extrapyramidal diseases. Rarely, it has been also reported as a side effect of different psychopharmacologic drugs, including selective serotonin reuptake inhibitors, tricyclic antidepressants, phenothiazines, olanzapine, clozapine¹ and risperidone.² To our best knowledge, there is only one article with descriptions of two patients who developed stuttering as a dose-dependent side effect of treatment with three different phenothiazine antipsychotics (chlorpromazine, trifluoperazine, and fluphenazine).³ However, a case of stuttering associated with the use of levomepromazine (also known as mepromazine or methotrimeprazine) has so far not been reported. Levomepromazine is a low-potency aliphatic phenothiazine antipsychotic characterized by strong sedative abilities⁴ and 5-HT2A:D2 affinity ratio 5:1.⁵ We present a case in which levomepromazine was implicated as a potential cause of stuttering.

Psychopharmacology BulletinVol. 42(1)
Zero hunger
Openalex Percentile: Top 100%
Stuttering Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.